Evidence map›Paper›PMID 27515248›Full record

ArticleHaematologica2016

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Howard A Liebman, Mansoor N Saleh, James B Bussel, O George Negrea, Heather Horne, William A Wegener, David M Goldenberg

Open access · goldAbstract readClinical Trial, Phase IComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Emerging Therapies in Immune Thrombocytopenia.Journal of clinical medicine · 2021
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Howard A LiebmanInternal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA liebman@usc.edu dmg.gscancer@att.net.
Mansoor N SalehGeorgia Cancer Specialists, Atlanta, GA, USA.
James B BusselPlatelet Disorders Center, Division of Pediatric Hematology-Oncology, New York Presbyterian Hospital, NY, USA.
O George NegreaLow Country Cancer Care Assoc., Savannah, GA, USA.
Heather HorneImmunomedics, Inc., Morris Plains, NJ, USA.
William A WegenerImmunomedics, Inc., Morris Plains, NJ, USA.
David M GoldenbergImmunomedics, Inc., Morris Plains, NJ, USA liebman@usc.edu dmg.gscancer@att.net.
Immunomedics (United States) · USGeorgia Cancer Specialists · USNewYork–Presbyterian Hospital · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared two dosing schedules for subcutaneous injections of a low-dose humanized anti-CD20 antibody, veltuzumab, in immune thrombocytopenia. Fifty adults with primary immune thrombocytopenia, in whom one or more lines of standard therapy had failed and who had a platelet count <30×10

Indexed as

Antibodies, Monoclonal, HumanizedAntibody FormationDose-Response Relationship, DrugDrug Administration ScheduleFemaleHemorrhageHumansMaleMiddle AgedPlatelet CountRecurrenceRemission InductionThrombocytopeniaAntibodies, Monoclonal, Humanizedveltuzumab

Identifiers

PMID27515248
PMCPMC5394874
OpenAlexW2517596751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.